Ascendis Pharma Reports Second Quarter 2025 Financial Results

Did the company provide any guidance or outlook for H2 2025 or FY 2025? How does the Q2 2025 revenue compare to the company's consensus estimates? What are the gross and operating margins for each product line in this quarter? What is the year‑over‑year growth rate for YORVIPATH® and SKYTROFA® revenues? Are there any notable changes in market share for YORVIPATH® or SKYTROFA® versus competitors? How does ASC's Q2 performance compare to peer companies in the same therapeutic area? How might the earnings results affect the short‑term price momentum and trading volume? Is there any information on the pipeline or upcoming regulatory milestones that could influence future earnings? What are the key drivers behind the revenue performance—price changes, volume growth, or new product launches? What is the impact of these results on the valuation multiples (e.g., P/E, EV/Revenue) for ASC?